Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1667521

registered interest
date	07/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antibiotics
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he plans to take steps to make (a) Cefiderocol and (b) Ceftazidimethose available on the NHS.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	220
answer	answer is ministerial correction date of answer 09/11/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. NICE published guidance in August 2022 recommending both ceftazidime with avibactam and cefiderocol for treating severe drug-resistant gram-negative bacterial infections. This was as part of a project to test a new health technology evaluation process and payment model for antimicrobial products. NHS England has now issued contracts with the suppliers and cefiderocol and ceftazidime with avibactamare available for clinicians to prescribe in line with NICE’s recommendations.</p> answering member constituency Colchester answering member printed Will Quince question first answered 09/11/2023 17:51:11 answering member 4423 label Biography information for Will Quince
tabling member	4131 label Biography information for Jim Shannon

1667523

registered interest
date	07/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Osteoporosis: Romosozumab
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has a planned timescale for when romosozumab will be available in the NHS for the treatment of Osteoporosis.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	222
answer	answer is ministerial correction date of answer 09/11/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. The NHS in England is legally required to fund medicines recommended by NICE, usually within three months of final guidance.</p><p>NICE published guidance in May 2022 recommending romosozumab for treating severe osteoporosis in people after menopause who are at high risk of fracture. Romosozumab is therefore available for clinicians to prescribe to NHS patients who meet the specified criteria, in line with NICE’s recommendations.</p> answering member constituency Colchester answering member printed Will Quince question first answered 09/11/2023 10:25:40 answering member 4423 label Biography information for Will Quince
tabling member	4131 label Biography information for Jim Shannon

1665720

registered interest
date	18/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Staff
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will publish a timescale for the implementation of the NHS Long Term Workforce Plan.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	203296
answer	answer is ministerial correction date of answer 23/10/2023 answer text <p>The NHS Long Term Workforce Plan sets out the steps the National Health Service and its partners need to take to deliver an NHS workforce that meets the changing needs of the population over the next 15 years.</p><p>The plan is backed by £2.4 billion over five years which will support the expansion and reform of education and training as set out in the plan.</p> answering member constituency Colchester answering member printed Will Quince question first answered 23/10/2023 14:46:41 answering member 4423 label Biography information for Will Quince
tabling member	4131 label Biography information for Jim Shannon

1665794

registered interest
date	18/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Innovative Medicines Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether (a) his Department and (b) NHS England plan to review the performance of the Innovative Medicines Fund.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	203304
answer	answer is ministerial correction date of answer 23/10/2023 answer text <p>We have no plans to review the Innovative Medicines Fund’s performance. Medicines for the Fund are identified through the National Institute for Health and Care Excellence’s (NICE) appraisal process in line with the published principles. While no new non-cancer medicine has yet entered managed access through the Fund, several technologies which have proceeded to routine funding had been identified, assessed and their suitability for the Fund discussed with the relevant manufacturers.</p><p>NICE and NHS England continue to engage with industry and track the pipeline of new medicines for possible candidates. The ringfenced £340 million funding for the Fund forms part of NHS England’s overall specialised commissioning budget. Any underspend on medicines funded through the Fund is diverted to other specialised services.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 203305 203306 question first answered 23/10/2023 10:29:52 answering member 4423 label Biography information for Will Quince
tabling member	4131 label Biography information for Jim Shannon

1665797

registered interest
date	18/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Innovative Medicines Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many medicines have qualified for (a) managed access and (b) interim funding under the Innovative Medicines Fund ahead of routine commissioning.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	203305
answer	answer is ministerial correction date of answer 23/10/2023 answer text <p>We have no plans to review the Innovative Medicines Fund’s performance. Medicines for the Fund are identified through the National Institute for Health and Care Excellence’s (NICE) appraisal process in line with the published principles. While no new non-cancer medicine has yet entered managed access through the Fund, several technologies which have proceeded to routine funding had been identified, assessed and their suitability for the Fund discussed with the relevant manufacturers.</p><p>NICE and NHS England continue to engage with industry and track the pipeline of new medicines for possible candidates. The ringfenced £340 million funding for the Fund forms part of NHS England’s overall specialised commissioning budget. Any underspend on medicines funded through the Fund is diverted to other specialised services.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 203304 203306 question first answered 23/10/2023 10:29:52 answering member 4423 label Biography information for Will Quince
tabling member	4131 label Biography information for Jim Shannon

1665798

registered interest
date	18/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Innovative Medicines Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how much and what proportion of allocated funding for the Innovative Medicines Fund has been disbursed since its launch in June 2022.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	203306
answer	answer is ministerial correction date of answer 23/10/2023 answer text <p>We have no plans to review the Innovative Medicines Fund’s performance. Medicines for the Fund are identified through the National Institute for Health and Care Excellence’s (NICE) appraisal process in line with the published principles. While no new non-cancer medicine has yet entered managed access through the Fund, several technologies which have proceeded to routine funding had been identified, assessed and their suitability for the Fund discussed with the relevant manufacturers.</p><p>NICE and NHS England continue to engage with industry and track the pipeline of new medicines for possible candidates. The ringfenced £340 million funding for the Fund forms part of NHS England’s overall specialised commissioning budget. Any underspend on medicines funded through the Fund is diverted to other specialised services.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 203304 203305 question first answered 23/10/2023 10:29:52 answering member 4423 label Biography information for Will Quince
tabling member	4131 label Biography information for Jim Shannon

1664846

registered interest
date	16/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Staff and Care Workers
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department is taking steps to provide financial support to (a) health and (b) social care workers who are affected by ultra-low emissions zones.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	202540
answer	answer is ministerial correction date of answer 20/10/2023 answer text <p>Most National Health Service staff on national contracts who necessarily incur charges in the performance of their duties, in relation to parking, garage costs, tolls and ferries shall be refunded these expenses on production of receipts, whenever these are available.</p><p>Most care workers are employed by private sector providers who set their pay and terms and conditions, independent of central government. Local authorities work with care providers to determine fee rates, which should take account of wage costs, based on local market conditions. Local authorities should assure themselves that providers are sufficiently remunerating staff to retain an effective workforce.</p><p>The Government has now made available up to £8.1 billion in additional funding over two years to support adult social care and discharge.</p> answering member constituency Colchester answering member printed Will Quince question first answered 20/10/2023 11:22:23 answering member 4423 label Biography information for Will Quince
tabling member	4131 label Biography information for Jim Shannon

1662748

registered interest
date	13/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cardiovascular System: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will increase (a) funding and (b) staffing levels for vascular care.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	200602
answer	answer is ministerial correction date of answer 19/10/2023 answer text <p>The Government has and will continue to prioritise investment into the National Health Service. Funding confirmed at the last Spending Review was on top of the historic long-term NHS settlement announced in 2018. Taken together with funding announced at the Autumn Statement 2022, this means that the NHS resource budget in England will increase in cash terms to £165.8 billion in 2024/25, up from £123.4 billion in 2019/20.</p><p>It is for local integrated care systems to determine the appropriate funding for vascular care for their populations. The NHS Long Term Workforce Plan commits to double the number of medical school training places. As these students graduate, we will work with stakeholders to ensure the commensurate growth in specialty training places is sustainable and focused in the service areas where need is greatest.</p><p>The cardiology specialty has seen a higher-than-average increase in the numbers of doctors working in the NHS. There are over 1,400 (63%) more doctors working in the cardiology specialty, including over 700 (89%) more cardiology consultants, compared to 2010.</p> answering member constituency Colchester answering member printed Will Quince question first answered 19/10/2023 14:35:29 answering member 4423 label Biography information for Will Quince
tabling member	4131 label Biography information for Jim Shannon

1662863

registered interest
date	13/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coeliac Disease: Endoscopy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to develop coeliac endoscopy NHS waiting lists.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	200717
answer	answer is ministerial correction date of answer 19/10/2023 answer text <p>Whilst patients on coeliac endoscopy pathways will be recorded, there are currently no plans to publish specialty level data for coeliac endoscopy National Health Service waiting lists.</p><p>NHS England collects and publishes monthly referral to treatment (RTT) data which is used to monitor NHS waiting times performance against the standards set out in the National Health Service Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012.</p><p>RTT data currently includes waiting list data for 23 treatment pathway categories, where one of these is gastroenterology.</p> answering member constituency Colchester answering member printed Will Quince question first answered 19/10/2023 14:36:57 answering member 4423 label Biography information for Will Quince
tabling member	4131 label Biography information for Jim Shannon

1663357

registered interest
date	13/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department plans to review the approval thresholds for new medications used by the National Institute for Health and Care Excellence.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	201211
answer	answer is ministerial correction date of answer 19/10/2023 answer text <p>There are no plans to review the standard cost-effectiveness range that the National Institute for Health and Care Excellence (NICE) uses in the evaluation of new medicines. NICE is responsible for the methods and processes it uses for health technology assessment, and concluded a comprehensive review of its methods and processes for the evaluation of new medicines in January 2022. As a result of the review, NICE introduced a new severity modifier that enables NICE to apply a weighting to medicines licensed for the treatment of more severe diseases. NICE is able to recommend the majority of medicines it appraises for use on the National Health Service, often as a result of confidential commercial agreements struck between the NHS and companies.</p> answering member constituency Colchester answering member printed Will Quince question first answered 19/10/2023 16:08:25 answering member 4423 label Biography information for Will Quince
tabling member	4131 label Biography information for Jim Shannon